<html xmlns="http://www.w3.org/1999/xhtml"><head>
        <meta http-equiv="Content-Type" content="text/html; charset=utf-8">
        <meta name="viewport" content="width=device-width, height=device-height, initial-scale=0.5, minimum-scale=0.5, user-scalable=yes, maximum-scale=2.0, target-densitydpi=device-dpi" />
				<meta name="robots" content="all"/>
        <meta name="description" content="description">
        <meta name="keywords" content="">
        <title>Page 272 - MIMS April 2020 E4</title>
<style type="text/css">
<!--
body {
	margin-left: 0px;
	margin-top: 0px;
	margin-right: 0px;
	margin-bottom: 0px;
}
  
#container {margin:50px auto;padding:0px;width:910px;}
#left-button{ width:90px; height:100%;float:left }
#middle{ width:730px; margin:0px; float: left;}
#right-button{ width:90px; float:left;}
html, body, div, ul, li, dl, dt, dd, h1, h2, h3, h4, h5, h6, form, input, dd,select, button, textarea, iframe, table, th, td { margin: 0; padding: 0; }
img { border: 0 none; displayblock}
span,ul,li,image{ padding:0px; margin:0px; list-style:none;}
#top-title{ width:714px; margin-bottom:10px; float:left; padding:0px 8px}
#top-title2{ width:320px;  float:right;}
#content{ width: 730px; float:left;float:left;word-wrap: break-word;}
#content-top{ width:730px; background-image:url(images/top_bg.jpg); height:56px; background-repeat:no-repeat; float:left;}
#content-top1{ width:70%; padding:16px 0px 0px 30px; font-family:Arial, Helvetica, sans-serif; font-size:24px; color:#636363;float:left;}
#content-top2{ width:60px; float:right; padding:25px 30px 0px 0px;font-family:Arial, Helvetica, sans-serif; font-size:11px; color:#2f2f2f; font-weight:bold; text-align:right}
#content-middle{ width:730px; background-image:url(images/middle_bg.jpg); background-repeat:repeat-y;float:left;}
#content-middle1{ width:475px; padding:25px 0px 25px 35px; font-family:Arial, Helvetica, sans-serif; font-size:12px; color:#636363; line-height:150%;float:left;}
#content-middle2{  padding:7px; float:right; margin:25px 35px 0px 0px; border:solid 1px #c8c8c9; background-color:#FFF; text-align:center}
#content-bottom{ width:730px; background-image:url(images/bottom_bg.jpg); background-repeat:no-repeat; height:58px;float:left;}
#content-bottom2{ width:110px; height:42px; margin:0px auto; padding-top:4px;}
#input{ width:58px; height:20px; background-color:#FFF; border:solid 1px #dfdfe0; color:#636363; text-align:center; font-size:11px;}
.font1{ font-family:Arial, Helvetica, sans-serif; font-size:10px; color:#2f2f2f;}
.font1 a:link{
	text-decoration: none;
    color:#2f2f2f;

}
.font1 a:visited{
	text-decoration: none;
    color:#2f2f2f;
	
}
.font1 a:hover{
	color: #2f2f2f;
	text-decoration: underline;

}



.text-container {
padding: 20px;
color: #333;
margin-top: 24px;
line-height: 22px;
border-top-left-radius: 3px;
border-top-right-radius: 3px;
}

.use-as-video {
float: right;
padding-left: 20px;
}
.cc-float-fix:before, .cc-float-fix:after {
content: "";
line-height: 0;
height: 0;
width: 0;
display: block;
visibility: hidden;
}
.use-as-video-img {
cursor: pointer;
position: relative;
width: 320px;
height: 180px;
}
.use-as-video-title {
font-size: 15px;
font-weight: bold;
color: #000000;
padding-bottom: 5px;
}
-->
</style>
<script type="text/javascript">
<!--
function MM_preloadImages() { //v3.0
  var d=document; if(d.images){ if(!d.MM_p) d.MM_p=new Array();
    var i,j=d.MM_p.length,a=MM_preloadImages.arguments; for(i=0; i<a.length; i++)
    if (a[i].indexOf("#")!=0){ d.MM_p[j]=new Image; d.MM_p[j++].src=a[i];}}
}

function MM_swapImgRestore() { //v3.0
  var i,x,a=document.MM_sr; for(i=0;a&&i<a.length&&(x=a[i])&&x.oSrc;i++) x.src=x.oSrc;
}

function MM_findObj(n, d) { //v4.01
  var p,i,x;  if(!d) d=document; if((p=n.indexOf("?"))>0&&parent.frames.length) {
    d=parent.frames[n.substring(p+1)].document; n=n.substring(0,p);}
  if(!(x=d[n])&&d.all) x=d.all[n]; for (i=0;!x&&i<d.forms.length;i++) x=d.forms[i][n];
  for(i=0;!x&&d.layers&&i<d.layers.length;i++) x=MM_findObj(n,d.layers[i].document);
  if(!x && d.getElementById) x=d.getElementById(n); return x;
}

function MM_swapImage() { //v3.0
  var i,j=0,x,a=MM_swapImage.arguments; document.MM_sr=new Array; for(i=0;i<(a.length-2);i+=3)
   if ((x=MM_findObj(a[i]))!=null){document.MM_sr[j++]=x; if(!x.oSrc) x.oSrc=x.src; x.src=a[i+2];}
}
//-->
</script>
</head>

<body onload="MM_preloadImages('images/next2.png','images/previous2.png')">
<div id="container">
<div id="left-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page271.html"><img src="images/previous_big.png" width="90" height="80" /></a></p>
</div>
<div id="middle">
  <div id="top-title"><span class="font1">Basic HTML Version</span>
    <div id="top-title2">
      <table width="100%" border="0" align="right" cellpadding="0" cellspacing="0">
        <tr>
        	<td width="66%"> </td>
          <td width="35%" style="display:none" align="right"><img src="images/content.png" width="19" height="16" /></td>
          <td width="31%" style="display:none" class="font1"><a href="">Table of Contents</a></td>
          <td width="6%"><img src="images/view.png" width="19" height="16" /></td>
          <td width="28%" class="font1"><a href="../../MIMS April 2020 E4.html#p=272">View Full Version</a></td>
        </tr>
      </table>
    </div>
  </div>
  <div id="content">
     <div id="content-top">
        <div id="content-top1">Page 272 - MIMS April 2020 E4</div>
        <div id="content-top2">P. 272</div>
     </div>
     <div id="content-middle">
     	
     	  <div class="text-container">
    <div class="use-as-video cc-float-fix">
      <a style="text-decoration: none;" href="../../MIMS April 2020 E4.html#p=272"><img src="../thumb/272.jpg" /></a>
    </div>

    <p class="use-as-video-title"></p>
    <pre style="white-space:pre-line"><code>Anti-Microbials - 18.2                                                         2020-04 / 235
       dyspeps., taste disturbs., abnorm.liv.funct.incl.hepatit./ cholestat.   Indications: U&LRTI, skin & soft tiss.infects., H. pylori eradicat.to   (S4) IV INJ, A568. 50 mg/ml.
       jaund., interstit.nephrit., ac.ren.fail., ser. skin reacts.incl.erythema   decr.recurr.of duod.ulc.in combinat. with a proton-pump inhibit.& an-  724181-008: 1 g vial, R296,56
       multiforme/Stev. John.syndr./tox.epiderm.necrolys., loc.reacts.at   other antibiot., mild to mod.otit.med.  Dosage: 15-20 mg/kg bm/day (ie.contin.infus.). 4-5 mg/kg bm 6 hrly.
       infus.site, arthralg., oed., photosens.  (S4) TABS 500, 38/20.1.1/0006  (ie.intermitt.admin.over 20-60 mins).
       Special precautions: Monit.pts.exper.ser. allerg. reacts., poss.  705031-001: 500 mg, 10, R113,32  Ac.pelv.inflamm.dis: 500 mg 6 hrly x3 days foll.by oral dos.250 mg x7 days.
       pseudomembr.colit., superinfect., imp.ren.funct., admin.tabs.1 hr   Dosage: Adults: 250-500 mg 2xdly.  Contraindications:. Concom.terfenadine/ astemizole/cisapride.
       bef./2 hrs.aft.concom.antacids, monit.digox.ser. lev., monit.ciclospor.  H.pylori eradicat: 500 mg 2xdly.in combinat.with appropr.antibiot.&   Side effects: Allerg./skin reacts., Stev.John.& tox. epiderm.necro-
       lev.& poss.dos.adjustm., monit.prothromb.time with concom.warfar.,   acid low agent.x7-10 days.  lys., loc.reacts., GI disturbs., pseudomembr. colit., revers.deafn.aft.
       Drug interactions: Ergot toxic.with ergot deriv., some macrolide   HIV pts.with atypic.Mycobact.infects: Adults: 500 mg 2xdly.   high dos., hepat. dysfunct., may aggrav.weakn.in myasthen. grav.
       antibiot.poss.interfer.with ciclospor. metab., poss.incr.digoxin conc.,   Use in conjunct.with other antimycobact. agents. Cont.as long as   Special precautions: Imp.hepat.funct., cross. placenta, pregn.
                                                                     st
       incr. ser. conc.of concom.meds.metab.by cytochrome P450 enzyme   clinic.& microbiologic. benef. demonstrat. Decr.effic.noted if treatm.   esp.1  trimest., monit. prothrombin times dur.concom. chron. cou-
       syst.,area und.theophylline plasma conc.-time curve incr.  exceeds 12 wks.  mar. type anticoag.ther., superinfects.
       CLACEE, (Aspen Pharmacare: Pharma) Abbott [P/S]  (S4) XL TABS, 43/20.1.1/0859  Drug interactions: Reduc.theophyll.dos.if used concom., poss.ac.ergot
                                     Indications: U&LRTI, skin & soft tiss.infects.
                                                                  toxic.with ergotamine/ dihydroergotamine, triazolam & midazolam clear.
       Clarithromycin.               717722-002: 500 mg, 5, R102,80  decr., lev.of meds.metabol.by cytochrome P450 elev., metabol.of astemi-
       Indications: U&LRTI, skin & soft tiss.infects., H. pylori eradicat.  717722-001: 500 mg, 10, R204,51  zole & terfenadine alt., cisapride lev.elev., zopiclone clear.decr., prothrom-
       decr.recurr.of duod.ulc.in combinat. with a proton-pump inhibit.&   Dosage: Adults: 500 mg once dly.with foodx7-14 days. Sev.infects:   bin times prolong.with chron.coumar. type anticoags.
       another antibiot., dissem. & localis. Mycobacterium avium/ Myco-  May be incr.to 1000 mg once daily.
       bacterium intracellulare infects in HIV-posit. adults in conjunct.with   (S4) ORAL SUSP, A39/20.1.1/0292, 0293  KETEK, Sanofi-Aventis [P/S]
       other antimycobact.           Indications: U&LRTI, mild to mod.sev.ac.otit. med., skin & soft tiss.  Telithromycin
       (S4) TABS, X/20.1.1/229, 29/20.1.1/0163  infects., H. pylori eradicat.to decr.recurr.of duod.ulc.in combinat. with   Indications: Community-acquir.pneumon./ac. exacerbat.of chron.
       704032-001: 250 mg, 10, R101,58  a proton-pump inhibit.& another antibiot.  bronchit./ac.sinusit./tonsillit. caus.by suscept.micro-organ.in pts.18
       704033-001: 500 mg, 10, R107,46  706758-001: 125 mg/5 ml, 50 ml, R83,90  yrs.& old. tonsillit./pharyngit.in pts.12 yrs & old.where high lev.
       704033-002: 500 mg, 14, R150,44  706759-001: 250 mg/5 ml, 50 ml, R154,10  micro-organ.resist.to beta-lactam/macrolide/ trimethoprim & sul-
       Dosage: Adults: 250-500 mg 2xdly.  Dosage: 1-2 yrs: 125 mg/5 ml: 2,5 ml 2xdly. 2-4 yrs: 125 mg/5 ml: 5   phamethoxazole anti-microb. meds./fail.ther.with these agents exper.
       H.pylori eradicat: 500 mg 2xdly.in combinat. with amoxycill.   ml 2xdly. or 250 mg/5 ml: 2,5 ml 2xdly. 4-8 yrs: 125 mg/5 ml: 7,5 ml   or where intol.to beta-lactam/macrolide/quinolones/ trimethoprim &
       1 000 mg 2x/day & omeprazole 20 mg dly.x7-10 days.  2xdly.or 250 mg/5 ml: 3,75 ml 2xdly. 8-12 yrs: 125 mg/ 5 ml: 10 ml   sulphamethoxazole anti-microb. meds
       HIV pts.with Mycobact.infects: 500 mg 2xdly. Cont.as long as   2xdly or 250 mg/5 ml: 5 ml 2xdly.  (S4) TABS, 35/20.1.1/0330
       clinic.& microbiologic.benef. demonstrat. Decr.effic.noted if treatm.  Contraindications: Concom.astemizole, terfenadine, cisapride &   702607-003: 400 mg, 10, R488,53
       exceeds 12 wks.               pimozide ther./pts. receiv. these ther.with pre-exist.card.abnormalit.,   Dosage: Adults & adolesc.over 12 yrs: 800 mg once dly.x5 days
       Contraindications: Concom.astemizole/ terfenadine/ cisapride/  porphyr., concom.colchicine, concom.ritonavir with clarithromyc. dos.  at bedt.to reduc.vis.disturb.& loss consciousn.potent. For commun.
       ergotamine/ dihydroergotamine & pimozide ther., safety in pregn.&   great. than 1 g/day, safety in pregn. & lactat.not est. Susp: also safety   acquir. pneumon. admin. x7-10 days.
       lactat.not est., concom.ritonavir with dos.great.than 1 g/day.  in infts. und.6 mnths.not est. XL tabs: also creatinine clear. &lt;30 ml/min.  Contraindications: Myasthen.grav., macrolide antibact.med.hy-
       Side effects: GI disturbs., tongue discol., hepat. dysfunct., hypogly-  Side effects: Leukopen., thrombocytopen., QT prolongat./ventric.  persens., hist.of hepatit.and/or jaund.with prev.admin., concom.er-
       caem., leukopen., thrombocytopen., allerg.reacts.incl.Stev.Johns.   tachycard.& torsades de pointes, CNS effs.incl.convuls.& psychos.,   got alkaloid derivat./cisapride/pimozide/astemizole/ terfenadine /
       syndr. & tox. epiderm. necrolysis, CNS effs. incl. convuls.& psychos.,   hypoglycaem., GI disturbs., tongue & tooth discol., pseudomembr.  simvastatin/lovastatin/atorvastatin/ cerivastatin & oral midazolam,
       hear.loss, QT prolongat./ ventric.tachycard.& torsades de pointes.  colit., hepat.dysfunct., pancreatit., skin reacts.incl.Stev.John.syndr.&   congenit./family hist of long QT syndr., known/acquir.QT-interv. pro-
       Special precautions: Imp.hepat./ren.funct., pseudomembr. colit.,   tox.epiderm. necrolysis, allerg.reacts., anaphylax., oral candidias.,   longat., pregn.& lactat., safety & effectiven.in pts. &lt;12 yrs.not est.
       other macrolide meds./ lincomycin & clindamycin cross-sens., excret.  deafn., tinnit., vertigo.  Side effects: Exacerbat.of myasthen.grav.incl. death & life threat.
       in human breast milk., monit.concom.quinidine/ disopyramide ser.lev.  Special precautions: Imp.hepat./ren.funct., rhabdomyolys.report.  rapid ac.resp.fail onset & progress., alt.liv.enzym., sev.hepatit.& liv.
       Drug interactions: Incr.levels of circulat. theophylline & carbamaze-  with concom.HMGCoA reduct. inhibit., incr.incid.of uveitis with con-  fail.with fatalit., blurr.vis., vis.disturbs., rarely loss of consciousn.
       pine, potent.warfarin eff., zidovudine ser.conc.decr., poss.elev.ser.lev. of   com. rifabutin & rifampic.than rifabutin alone, other macrolide meds./  preced.by vag.sympts., GI disturbs., allerg. reacts.incl. angioed.&
       meds.metabol.by the cytochrome P450 syst., incr. incid.of uveitis when   lincomycin & clindamycin cross-resist., monit.prothrom.time with an-  anaphylax., cholestat. jaund., CNS effs., paraesthes., eosinophil.,
       rifabutin co-admin.with clarithromycin, elev.digox.serum conc., tor-  ticoags., monit. digox.& theophyll.ser.conc., admin. zidovudine 4 hrs.  taste disturbs., parosmia., vag.monilias., eczema, erythem. multi-
       sades de pointes with concom.quinidine/disopyramide, QT-prolong.&   apart, excret.in human breast milk., safety & effic.in combinat.with   forme, musc.cramps, flush., atrial arrhythm., hypotens., bradycard.,
       card.arrhythm.with terfenadine, astemizole, cisapride, & pimozide.  proton-pump inhibit.other than omeprazole not est., pseudomembr.   palpitat., QT/QTc interv. prolongat.
                                                                  Special precautions: Observ.for & discont.if S&S of hepat.fail.
       CLAREN, Specpharm [P/S]       colit., discont.if signs of hepat. dysfunct. develop, hypoglycaem.re-  pres., hepat.reacts.gen.assoc. with underly.dis/concom.meds., poss.
       Clarithromycin.               port.in some pts. on oral hypoglycaem./insul., monit.ser.lev.of con-  pseudomembr. colit., QT-interv.prolongat.potent. with poss.ventric.
       Indications: Mild to mod.sev.U&LRTI, skin & soft tiss.infects., H.   com. meds metabol.by cytochrome P450 enzyme, colchicine toxic.  dysrhythm., avoid with congenit. prolongat.of QTc interv./uncorrect.hy-
       pylori eradicat.in combinat.with a proton-pump inhibit.& another   with fatalit.report.esp.in elderly/ren.insuffic.  pokalaem./ hypomagnesaem., bradycard/concom.class1A or Class III
       antibiot.to decr. recurr.of duod.ulc.  Drug interactions: Rifabutin & rifampicin decr. ser. conc., theophyl-  antidysrhythm.meds., correct.risk fact.for QT prolongat.(hypokalaem/
       (S4) GRANS FOR SUSP, 41/20.1.1/0249, 0250  line area under plasma curve incr., QT-prolong.& card.arrhythm.with   hypomagnesaem.& bradycard.) bef.init.treatm., driv.motor vech./ op-
       716627-001: 125 mg/5 ml, 60 ml, R75,00  terfenadine, astemizole, cisapraide, & pimozide, potent. warfarin   erat. machin./hazard.activ.due to vis.disturb.& loss of consciousn.po-
                                     eff., elev.digox.serum conc., poss. elev. ser.lev. of meds.metabol.by
       716628-001: 250 mg/5 ml, 60 ml, R150,01                    tent., concom.meds.that are CYP3A4 substrates & not recomm.unless
       Dosage: Adults: 250-500 mg 2xdly.  the cytochrome P450 syst., zidovudine ser.conc.decr., metabol inhibit.   plasma concs.& advers.events can be monit., interupt. statin treatm.
                                     by ritonavir & poss other HIV-protease inhibit. & non-nucleoside re-
       H.pylori eradicat: 500 mg 2xdly.in combinat. with appropr antibiot   dur.ther., concom.digox., observ.1 hr. interv.bef.admin.theophyll.to re-
       & acid low.agent x7-10 days. Safety & effic.with proton-pump inhibit.  verse transcript. inhibit., incr.risk of colchicine toxicity esp.with ren.   duc.GI effs., concom. benzodiazep.metabol.by CYP3A4, avoid treatm.
                                     impairm. ranitidine conc.incr.
       other than omeprazole not est.                             dur. & 2wks.aft.treatm.with CYP3A4 induc. (eg. rifampicin/phenytoin/
       HIV pts.with atypic.mycobact.infects: 500 mg 2xdly. Cont.  CLARITHROMYCIN UNICORN 500 XL,    carbamazepine & St John Wort), sev.ren.impairm.
       as long as clinic.& microbiologic. benef. demonstrat. Decr.effic.  (Unicorn) Sandoz [P/S]   Drug interactions: Cisapride peak plasma conc. incr.2-fold, sev.
       noted if treatm. exceeds 12 wks. Use in conjunct.with other anti-  Clarithromycin  vasoconstrict.& poss.necros.with ergot alkaloid.derivat., ser.lev.of
       microb. agents.               Indications: U&LRTI, skin & soft tiss.infects.  pimozide/ astemizole & terfenadine incr.poss.prolong.QT interv.,
       Childr: Usual durat: 5-10 days depend.on sev.of infect. Admin.2xdly.  (S4) XL TABS, 43/20.1.1/0860  C max.& AUC of simvastatin.incr., digox. plasma conc.incr., midazolam
       8-11 kg (1-2 yrs): 62,5 mg. 12-19 kg (2-4 yrs): 125 mg. 20-29 kg   721268-001: 500 mg, 5, R102,24  half-life incr., C max.& AUC of sotalol.decr., plasma conc.incr.by itra-
       (4-8 yrs): 187,5 mg. 30-40 kg (8-12 yrs): 250 mg.  Dosage: Admin with food & swall.whole.  conaz. & ketoconaz., C max.& AUC decr.by rifampicin.
       Contraindications: Concom.astemizole/ cisapride /pimozide &   Adults: 500 mg once dly.usual.x7-14 days. May be incr.to 1 000 mg
       terfenadine, porphyr., safety & effic.in pregn./lactat. & infts.und.6   once dly.in more sev.infects.  KLARIBIN, Aurobindo [P/S]
       mnths not est.                Contraindications: Creatinine clear.&lt;30 ml/min., concom.astemi-  Clarithromycin
       Side effects: Leukopen., thrombocytopen., hypersens./ allerg.reacts.  zole, cisapride, pimozide, ergotamine or dihydroergotamine/pts.re-  Indications: U&LRTI, skin & soft tiss.infects., mild to mod ac.otit.
       incl. anaphylax., hypoglycaem., headache, CNS eff.incl.insomn./ diso-  ceiv. these ther. with pre-exist.card. abnormalit.& electrol. disturbs.,   media, H.pylori eradicat.to decr.recurr.of duod.ulc.in combinat.with a
       rientat./ depersonalisat., dizzin., convuls., vertigo, tinnit., hear.loss, QT   porphyr., safety in pregn.& lactat.not est.  proton-pump inhibit.& another antibiot.
       prolongat./ventric. tachycard. & torsades de pointes, GI disturbs., glos-  Side effects: Oral candidias., leukopen., thrombocytopen., QT prolon-  (S4) TABS, 42/20.1.1/0852, 0853
       sit., stomatit., oral candidias., tong./tooth discolourat., pseudomembr.  gat./ventric.tachycard. & torsades de pointes, CNS effs., headache,   720976-001: 250 mg, 10, R89,91
       colit., hepatocellul.&/ cholestat. hepatit., pancreatit., skin reacts. incl.   dizzin., convuls., parosm., hypoglycaem., psych. disords., GI disturbs.,   720977-001: 500 mg, 10, R97,62
       Stev. John.syndr.& tox.epiderm.necrolysis.  tongue & tooth discol., pseudomembr. colit., hepatit., jaund., hepat.  Dosage: Adults & childr.old than 12 yrs: 250 mg 2xdly. May be
       Special precautions: Excret.in breast milk, liv. funct./ sev.ren.funct.  fail., pancreatit., deafn., tinnit., vertigo, skin reacts. incl.Stev.John.syn-  incr.to 500 mg 2xdly.in more sev.infects.
       impairm., rhabdomyolys. report with HMGCoA reduct.inhibit., incr.  dr.& tox.epiderm.necrolys., hypersens., anaphylax., interstit.nephrit.  H.Pylori eradicat: 500 mg 2xdly.in combinat. with appropr.antibiot.&
       incid.of uveitis when rifabutin & rifampicin co-admin. compar.to ri-  Warnings and special precautions: Liv. funct.impairm., sev.ren.  acid.low.agent x7-10 days.
       fabutin alone, monit.theophyll.ser. conc., cross resist.report.with other   funct.impairm., excret.in breast milk, not suit.for pts.with creat.clear.of   Concom.ritonavir: 1 g/day not to be exceed.
       macrolides/ lincomycin & clindamycin, concom.zidovudine dos. to be   less than 50 ml./min., discont.if signs of hepat. dysfunct. devel., con-  Contraindications: Concom.astemizole/ cisapride/ pimozide/er-
       taken at least 4 hrs apart, discont.if signs of hepat. dysfunct.develop,   com.oral hypoglycaem./insul., immunocompromis.pts.treat.with high.  gotamine/ dihydroergotamine/ HMG-CoA reduct.inhibits., porphyr.,
       hepat.fail.somet.fatal usuall. assoc.with ser.underly.dis.&/ concom.   dos.longt., pts. present.with diarrh., concom.theophyll., colchicine   safety & effic.in pregn.& lactat.not est., concom. colchicine in pts.
       meds., immunocomprom.pts.treat.with high.dos., monit. concom.  not to be used concom., monit.INR/ prothromb.time, rhabdomyolys.  with ren./liv.impairm. tak.P-glycoprot.inhibits./strong CYP34A inhibit.,
       warfarin/digoxin/carbamazepine or other meds.metabol.by cyto-  report.with concom. HMGCoA reduct.inhibit., fatal colchicine toxic.  safety & effic.in infts.und.6 mnths.not est., childr.&lt; 12 yrs., safety &
       chrome P450 syst., max. 1 g/day when admin.concurr.with ritonavir.  esp. in elderly with ren.insuff.  effic.of concom.proton-pump inhibit.other than omeprazole not est.
       Drug interactions: Rifabutin & rifampicin decr. ser. conc., incr.  Drug interactions: Decr.ser.conc./ uveit.incid. with rifabutin & ri-  Side effects: Hepat.dysfunct.incl.incr.liv.enzym.& hepatocellul. &/
       lev.of circulat.theophylline, poss. decr. of zidovudine steady-state   fampicin, incr.AUC with theophyll., other macrolid.cross.-sens., incr.   cholestat.hepatit.with somet.fatal outcome, hypoglycaem., oral candid-
       conc., metabol. inhibit. with ritonavir/other HIV prot.inhibits./non-  ranitidine conc., incr.ser.conc.with ritonavir, decr. zidovudine conc.,   ias., GI disturbs. incl.sev.diarrh.which may be bloody, fev., ac.pancreatit.,
       nucleoside reverse transcript.inhibits., effs.of anticoags. potent.,   warfar.effs.potent., poss.incr.ser conc.of meds.metabol.by the cy-  vag.infects., bld.dyscras., allerg. reacts. incl.anaphylax., psychot.disor-
       digox.ser.conc.incr., QT-prolong. & card.arrhythm.incl.torsades de   tochrome P450 syst.  ds., headache, dizzin., vertigo, convuls., trem., CNS effs., hear.loss, tin-
       pointes somet. fatal with astemizole/cisapride/pimozide/ terfena-  nit., QT prolongat./ventric. tachycard.& torsades de pointes, palpitat.,
       dine, poss.incr.lev.of carbamazepine/ other meds. metabol.by cyto-  ERYTHROCIN, Pharmaco [P/S]  epistax., glossit., stomatit., tongue & tooth discol., hyperhidros., skin re-
       chrome P450 enzyme syst.      Erythromycin lactobionate equiv.to erythromycin  acts.incl.Stev.Johns.syndr.& tox. epiderm.necrolys., erysipelas, erythras-
                                     Indications: U&LRTI, skin & soft tiss.infects., non-gonococ.male   ma, myalg., rhabdomyolys., myopathy, interstit. nephrit., ren.fail., asthen.
       CLARIHEXAL, (Sandoz) Hexal [P/S]  urethrit.& fem.pelv.infects., long-term prophylax.of rheum.fev.& early   Warnings and special precautions: Excret.in breast milk, embryo
       Clarithromycin.               syphill. in penicill.allergy, tetan., Legionnaires dis.  toxic.in anim., imp.hepat. funct., discont.if hepatit.S&S occur, sev.ren.</code></pre>
     	</div>
    
     </div>
     <div id="content-bottom">
       <div id="content-bottom2">
         <table width="110" border="0" cellspacing="0" cellpadding="0">
           <tr>
             <td width="22%" height="44"><a href="page271.html"><img src="images/previous.png" width="26" height="19" id="Image2" onmouseover="MM_swapImage('Image2','','images/previous2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
             <td width="43%">
             	&nbsp;&nbsp;&nbsp;<a href="page267.html">267</a>&nbsp;&nbsp;&nbsp;<a href="page268.html">268</a>&nbsp;&nbsp;&nbsp;<a href="page269.html">269</a>&nbsp;&nbsp;&nbsp;<a href="page270.html">270</a>&nbsp;&nbsp;&nbsp;<a href="page271.html">271</a>&nbsp;&nbsp;&nbsp;<a href="page272.html">272</a>&nbsp;&nbsp;&nbsp;<a href="page273.html">273</a>&nbsp;&nbsp;&nbsp;<a href="page274.html">274</a>&nbsp;&nbsp;&nbsp;<a href="page275.html">275</a>&nbsp;&nbsp;&nbsp;<a href="page276.html">276</a>&nbsp;&nbsp;&nbsp;<a href="page277.html">277</a>
             </td>
             <td width="35%"><a href="page273.html"><img src="images/next.png" width="26" height="19" id="Image1" onmouseover="MM_swapImage('Image1','','images/next2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
           </tr>
         </table>
       </div>
     </div>
  </div>
</div>
<div id="right-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page273.html"><img src="images/next_big.png" width="90" height="80" /></a></p>
</div>


</div>

</body>
</html>
